Cancer epigenomics investigates heritable alterations in gene expression not involving sequence changes in DNA but are very important in the development, progression, and response to therapy in tumors. The session "Cancer Epigenomics" aims to understand such modifications and their utility as diagnostic, prognostic, and therapeutic targets.".
Core epigenetic processes are DNA methylation, histone modification, chromatin remodeling, and regulation by non-coding RNA. Abnormality of these processes drives the activation of oncogenes or silencing of tumor suppressors and leads to uncontrolled cell growth, metastasis, and resistance to therapy. Epigenomic analysis offers information on heterogeneity of the tumor and patient-specific disease pathways and directs precision cancer medicine approaches.
The session covers novel therapies aimed at epigenetic regulators, such as inhibitors of DNA methyltransferases and histone-modifying enzymes, and combination therapies with immunotherapy or targeted therapy. Next-generation sequencing, single-cell epigenomics, and bioinformatics tools are advanced technologies that facilitate comprehensive epigenetic landscape characterization, enhancing early detection and therapeutic decision-making.
Participants will learn about the mechanisms, clinical uses, and research progresses in cancer epigenomics. This session highlights how deciphering and targeting epigenetic modifications can result in novel, precision therapies, improve treatment outcomes, and move the precision oncology field forward.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
